A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies

Novartis Pharmaceuticals225 enrolled

Overview

This is a Phase I/II, multi-center, open-label study, composed with a Phase I part (dose-escalation phase) followed by a Phase II part (expansion phase). The dose escalation phase was designed to determine as primary objective the maximum tolerated dose (MTD) or recommended Phase II dose (RP2D) of EGF816 monotherapy in adult subjects with locally advanced (stage IIIB) or metastatic (stage IV) NSCLC harboring specific EGFR mutations. Patients may have or not have received prior lines of antineoplastic therapy. An adaptive Bayesian Logistic Regression Model (BLRM) employing the escalation with overdose control (EWOC) principle will be used during the dose escalation part for dose level selection and MTD recommendation. The primary objective of the Phase II part is to estimate antitumor activity of EGF816 as measured by overall response rate (ORR) determined by Blinded Independent Review Committee (BIRC) assessment in accordance to RECIST 1.1.

Following completion of screening procedures and confirmation of patient eligibility, the participants are enrolled in the study. The study treatment begin on Cycle 1, Day 1 with the first administration of EGF816. A treatment cycle is defined as 28 days. Oral EGF816 is administered once daily on a continuous schedule until patient experiences unacceptable toxicity, progressive disease (PD), and/or treatment is discontinued at the discretion of the investigator, patient withdrawal of consent, or due to any other reasons. Treatment with EGF816 may be continued beyond RECIST 1.1 defined PD, if, in the judgment of the investigator, there is evidence of clinical benefit and the patient wishes to continue with the study treatment.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

225

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: (For all patients unless otherwise specified) * Histologically or cytologically confirmed locally advanced (stage IIIB not amenable to definitive multi-modality therapy including surgery) or metastatic (stage IV) EGFR mutant NSCLC. * Patients with controlled brain metastases * ECOG performance status: Phase I part: 0, 1, or 2; Phase II part: 0 or 1 * Presence of at least one measurable lesion according to RECIST 1.1 per investigator assessment * Patients who are either Hepatitis B surface antigen (HBsAg) positive or hepatitis B virus (HBV)-DNA positive must be willing and able to take antiviral therapy 1-2 weeks prior to 1st dose of EGF816 treatment and continue on antiviral therapy for at least 4 weeks after the last dose of EGF816 * Patients must have negative hepatitis C antibody (HCV-Ab) or positive HCV-Ab but undetectable level of HCV-RNA. Note: patients with detectable HCV-RNA are not eligible for the study. * For Phase I: patients must have failed no more than 3 lines of any systemic antineoplastic therapy for advanced NSCLC, including EGFR-TKI * For Phase II: patients must be naïve from any systemic antineoplastic therapy in the advanced setting. Patients who have failed no more than 1 cycle of systemic antineoplastic therapy in the advanced setting are allowed. Exclusion criteria: (For all patients unless otherwise specified) * Patients with a history or presence of interstitial lung disease (ILD) or interstitial pneumonitis, including clinically significant radiation pneumonitis (i.e. affecting activities of daily living or requiring therapeutic intervention) * Presence or history of another malignancy * Undergone a bone marrow or solid organ transplant * Known history of human immunodeficiency virus (HIV) seropositivity * Patients receiving concomitant immunosuppressive agents or chronic corticosteroids use at the time of study entry except for control of brain metastases, topical applications, inhaled sprays, eye drops or local injections * Patients with clinically significant, uncontrolled heart disease * Any prior therapies ≤ 4 weeks prior to the first dose of study treatment * Patients who are receiving treatment with medications that are known to be strong inhibitors or inducers of CYP3A4/5 and cannot be discontinued 1 week prior to the start of EGF816 treatment and for the duration of the study. * Patients who have impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of EGF816 * Patients who are receiving treatment with any enzyme-inducing anticonvulsant that cannot be discontinued at least 1 week before first dose of study treatment, and for the duration of the study * Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception * Sexually active males unless they use a condom during intercourse while taking drug and for 3 months after stopping treatment Other protocol-defined inclusion and exclusion criteria may apply.

Locations (14)

Massachusetts General Hospital Mass General

Boston, Massachusetts, United States

Memorial Sloan Kettering Oncology Department

New York, New York, United States

Novartis Investigative Site

Toronto, Ontario, Canada

Novartis Investigative Site

Berlin, Germany

Novartis Investigative Site

Cologne, Germany

Novartis Investigative Site

Nagoya, Aichi-ken, Japan

Novartis Investigative Site

Fukuoka, Fukuoka, Japan

Novartis Investigative Site

Zoetermeer, Netherlands

Novartis Investigative Site

Singapore, Singapore

Novartis Investigative Site

Seoul, South Korea

...and 4 more locations

Outcomes

Primary Outcomes

Number of Participants With Dose Limiting Toxicities (DLTs) (Phase I Part)

Number of participants with DLTs during the first 28 days of therapy. A DLT is defined as an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first cycle of treatment with EGF816 and meets any of the criteria described in the protocol. A participant with multiple occurrences of DLTs under one treatment is counted only once.

Time frame: First 28 days of dosing

Overall Response Rate (ORR) by Blinded Independent Review Committee (BIRC) (Phase II Part)

ORR is defined as the percentage of patients with a best overall response of complete response (CR) or partial response (PR) determined by BIRC assessment in accordance to Response Evaluation Criteria in Solid Tumors (RECIST 1.1).

Time frame: From baseline up to 64 weeks

Secondary Outcomes

Progression-free Survival (PFS) by Investigator Assessment (Phase I & Phase II Parts)

PFS is defined as time from date of first dose of study treatment to date of first documented disease progression or death due to any cause determined by Investigator assessment in accordance to RECIST 1.1

Time frame: At least 24 weeks up to approx. 9 years

Duration of Response (DOR) by Investigator Assessment (Phase I & II Parts)

DOR is defined as the time from first documented response (PR or CR) to the date of first documented disease progression or death due to any cause determined by Investigator assessment in accordance to RECIST 1.1

Time frame: At least 24 weeks up to approx. 9 years

Observed Maximum Plasma Concentration (Cmax) of EGF816 and Metabolite LMI258 (Phase I & Phase II Part)

To characterize the PK properties of EGF816 and metabolite LMI258, Cmax will be calculated (Phase I \& II parts). Cmax is maximum (peak) observed plasma drug concentration (mass x volume-1).

Time frame: Cycle (C) 1 Day (D) 1 (pre-dose and 0.5,1,2,3,4,6,8,12 and 24 hours (hrs) post-dose), C1D15 (pre-dose and 0.5,1,2,3,4,6,8,12 and 24 hrs post-dose) (for Phase I part only) and C2D1 (pre-dose and 0.5,1,2,3,4,6,8,12 and 24 hrs post-dose).

Time to Maximum Plasma Concentration (Tmax) of EGF816 and Metabolite LMI258 (Phase I & Phase II Part). Tmax is the Time to Reach Maximum (Peak) Plasma Drug Concentration (Time).

To characterize the PK properties of EGF816 and metabolite LMI258, Tmax will be calculated (Phase I \& II parts). Tmax is the time to reach maximum (peak) plasma drug concentration (time).

Area Under the Serum Concentration-time Curve From Time Zero to the End of the Dosing Interval Tau (AUCtau) of EGF816 and Metabolite LMI258 (Phase I & Phase II Part)

To characterize the PK properties of EGF816 and metabolite LMI258, AUCtau will be calculated (Phase I \& II parts). AUCtau is the AUC calculated to the end of a dosing interval (tau) (amount x time x volume-1).

Percentage Change From Baseline in H-score for Immunohistochemistry (IHC) Biomarkers From Tumor Tissue Samples (Phase I Part)

Changes in EGFR signaling pathway of newly obtained tumor samples following EGF816 treatment were evaluated by IHC of three pharmacodynamics (PD) biomarkers: p-EGFR, p-AKT and p-ERK. The assigned H-score semi-quantitatively assessed the expression level of these protein markers and their phosphorylated forms.

Time frame: Baseline and Cycle 1 Day 15

Overall Response Rate (ORR) by Investigator Assessment (Phase I & II Parts)

ORR is defined as percentage of patients with best overall response of partial response (PR)+ complete response (CR) determined by Investigator assessment in accordance to RECIST 1.1

Time frame: At least 24 weeks up to approx. 4 years

Disease Control Rate (DCR) by Investigator Assessment (Phase I & II Parts)

DCR is defined as the proportion of patients with best overall response of CR, PR, or SD determined by Investigator assessment in accordance to RECIST 1.1

Time frame: At least 24 weeks up to approx. 4 years

Time to Response (TTR) by Investigator Assessment (Phase I & II Parts)

TTR is defined as the time from the date of the first dose to the date of first documented response (CR or PR) determined by Investigator assessment in accordance to RECIST 1.1

Time frame: At least 24 weeks up to approx. 9 years

Number of Participants With Dose Interruptions and Dose Reductions (Phase I & II Parts)

Assessment of the tolerability of EGF816 will be performed continuously during the treatment phase

Time frame: At least 24 weeks up to approx. 9 years

Duration of Response (DOR) by BIRC (Phase II Part)

DOR is defined as the time from first documented response (PR or CR) to the date of first documented disease progression or death due to any cause determined by BIRC in accordance to RECIST 1.1

Time frame: At least 24 weeks up to approx. 9 years

Disease Control Rate (DCR) by BIRC (Phase II Part)

DCR is defined as the percentage of patients with best overall response of CR, PR, or SD determined by BIRC in accordance to RECIST 1.1

Time frame: At least 24 weeks up to approx. 9 years

Progression-Free Survival (PFS) by BIRC (Phase II Part)

PFS is defined as time from date of first dose of study treatment to date of first documented disease progression or death due to any cause determined by BIRC in accordance to RECIST 1.1

Time frame: At least 24 weeks up to approx. 9 years

Time to Response (TTR) by BIRC (Phase II Part)

TTR is defined as as the time from the date of first dose of study treatment to the date of first documented response (CR or PR) determined by by BIRC in accordance to RECIST 1.1

Time frame: At least 24 weeks up to approx. 9 years

Overall Survival (OS) (Phase II Part)

OS is defined as the time from first dose of the study treatment to the date of death due to any cause.

Time frame: At least 24 weeks up to approx. 9 years

A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies

Overview

Conditions

Interventions

Eligibility

Locations (14)

Outcomes

Primary Outcomes

Secondary Outcomes